{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T15:32:16Z","timestamp":1787239936903,"version":"build-2736575974"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,6,28]],"date-time":"2022-06-28T00:00:00Z","timestamp":1656374400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001409","name":"Department of Science and Technology, Ministry of Science and Technology, India","doi-asserted-by":"publisher","award":["SB\/S2\/JCB-052\/2015"],"award-info":[{"award-number":["SB\/S2\/JCB-052\/2015"]}],"id":[{"id":"10.13039\/501100001409","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Microbiology, Immunology and Infection"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jmii.2022.06.003","type":"journal-article","created":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T12:14:21Z","timestamp":1656936861000},"page":"163-171","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"title":["Combined immunotherapeutic effect of Leishmania-derived recombinant aldolase and Ambisome against experimental visceral leishmaniasis"],"prefix":"10.1016","volume":"56","author":[{"family":"Keerti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Narendra Kumar","family":"Yadav","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sumit","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0466-4771","authenticated-orcid":false,"given":"Sneha","family":"Ratnapriya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5985-0734","authenticated-orcid":false,"given":"Amogh Anant","family":"Sahasrabuddhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anuradha","family":"Dube","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jmii.2022.06.003_bib1","doi-asserted-by":"crossref","first-page":"9872095","DOI":"10.1155\/2018\/9872095","article-title":"Current visceral leishmaniasis research: a research review to inspire future study","volume":"2018","author":"Bi","year":"2018","journal-title":"BioMed Res Int"},{"issue":"10151","key":"10.1016\/j.jmii.2022.06.003_bib2","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1016\/S0140-6736(18)31204-2","article-title":"Leishmaniasis","volume":"392","author":"Burza","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.jmii.2022.06.003_bib3","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2012.00251","article-title":"Immunobiology of visceral leishmaniasis","volume":"3","author":"Kumar","year":"2012","journal-title":"Front Immunol"},{"issue":"6","key":"10.1016\/j.jmii.2022.06.003_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0008272","article-title":"Conversion of asymptomatic infection to symptomatic visceral leishmaniasis: a study of possible immunological markers","volume":"14","author":"Das","year":"2020","journal-title":"PLoS Neglected Trop Dis"},{"issue":"5","key":"10.1016\/j.jmii.2022.06.003_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0006375","article-title":"New insights into leishmaniasis in the immunosuppressed","volume":"12","author":"Akuffo","year":"2018","journal-title":"PLoS Neglected Trop Dis"},{"issue":"7","key":"10.1016\/j.jmii.2022.06.003_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pntd.0008221","article-title":"Post kala-azar dermal leishmaniasis: a threat to elimination program","volume":"14","author":"Gedda","year":"2020","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.jmii.2022.06.003_bib7","doi-asserted-by":"crossref","DOI":"10.1186\/s40249-016-0112-2","article-title":"Current challenges in treatment options for visceral leishmaniasis in India: a public health perspective","volume":"5","author":"Singh","year":"2016","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.jmii.2022.06.003_bib8","first-page":"1","article-title":"Chemotherapeutics of visceral leishmaniasis: present and future developments","author":"Sundar","year":"2017","journal-title":"Parasitology"},{"key":"10.1016\/j.jmii.2022.06.003_bib9","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.3389\/fimmu.2017.01943","article-title":"Immunomodulatory therapy of visceral leishmaniasis in human immunodeficiency virus-coinfected patients","volume":"8","author":"Adriaensen","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jmii.2022.06.003_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.2147\/VDT.S110654","article-title":"Management of visceral leishmaniasis with therapeutic vaccines","volume":"6","author":"Rawat","year":"2016","journal-title":"Vaccine Dev Ther"},{"key":"10.1016\/j.jmii.2022.06.003_bib11","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","article-title":"Cancer immunotherapy: the beginning of the end of cancer?","volume":"14","author":"Farkona","year":"2016","journal-title":"BMC Med"},{"issue":"Suppl","key":"10.1016\/j.jmii.2022.06.003_bib12","doi-asserted-by":"crossref","first-page":"S325","DOI":"10.1093\/infdis\/jis197","article-title":"Adjunct immunotherapies for tuberculosis","volume":"205","author":"Uhlin","year":"2012","journal-title":"J Infect Dis"},{"issue":"3","key":"10.1016\/j.jmii.2022.06.003_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.it.2010.12.006","article-title":"Immunotherapy for persistent viral infections and associated disease","volume":"32","author":"van der Burg","year":"2011","journal-title":"Trends Immunol"},{"issue":"2","key":"10.1016\/j.jmii.2022.06.003_bib14","first-page":"198","article-title":"Immunotherapy \u2013 vaccines for allergic diseases","volume":"4","author":"Wu","year":"2012","journal-title":"J Thorac Dis"},{"issue":"4","key":"10.1016\/j.jmii.2022.06.003_bib15","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1004857","article-title":"Integrating antimicrobial therapy with host immunity to fight drug-Resistant infections: classical vs. adaptive treatment","volume":"12","author":"Gjini","year":"2016","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.jmii.2022.06.003_bib16","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2147\/DDDT.S146521","article-title":"Leishmaniasis in humans: drug or vaccine therapy?","volume":"12","author":"Ghorbani","year":"2018","journal-title":"Drug Des Dev Ther"},{"issue":"17","key":"10.1016\/j.jmii.2022.06.003_bib17","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.vaccine.2018.03.027","article-title":"Immunotherapeutic potential of Leishmania (Leishmania) donovani Th1 stimulatory proteins against experimental visceral leishmaniasis","volume":"36","author":"Keerti","year":"2018","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jmii.2022.06.003_bib18","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14728214.2012.748036","article-title":"Liposomal amphotericin B as a treatment for human leishmaniasis","volume":"17","author":"Balasegaram","year":"2012","journal-title":"Expert Opin Emerg Drugs"},{"issue":"2","key":"10.1016\/j.jmii.2022.06.003_bib19","doi-asserted-by":"crossref","first-page":"159","DOI":"10.4103\/0974-777X.62886","article-title":"Liposomal amphotericin B and leishmaniasis: dose and response","volume":"2","author":"Sundar","year":"2010","journal-title":"J Glob Infect Dis"},{"issue":"2","key":"10.1016\/j.jmii.2022.06.003_bib20","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0004415","article-title":"Combined immune therapy for the treatment of visceral leishmaniasis","volume":"10","author":"Faleiro","year":"2016","journal-title":"PLoS Neglected Trop Dis"},{"issue":"3","key":"10.1016\/j.jmii.2022.06.003_bib21","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.4049\/jimmunol.166.3.1912","article-title":"The hamster as a model of human visceral leishmaniasis: progressive disease and impaired generation of nitric oxide in the face of a prominent Th1-like cytokine response","volume":"166","author":"Melby","year":"2001","journal-title":"J Immunol"},{"issue":"1","key":"10.1016\/j.jmii.2022.06.003_bib22","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0086073","article-title":"Characterization of glycolytic enzymes--rAldolase and rEnolase of Leishmania donovani, identified as Th1 stimulatory proteins, for their immunogenicity and immunoprophylactic efficacies against experimental visceral leishmaniasis","volume":"9","author":"Gupta","year":"2014","journal-title":"PLoS One"},{"issue":"5","key":"10.1016\/j.jmii.2022.06.003_bib23","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1002\/pmic.200600725","article-title":"Proteomic approach for identification and characterization of novel immunostimulatory proteins from soluble antigens of Leishmania donovani promastigotes","volume":"7","author":"Gupta","year":"2007","journal-title":"Proteomics"},{"issue":"1","key":"10.1016\/j.jmii.2022.06.003_bib24","doi-asserted-by":"crossref","first-page":"470","DOI":"10.4049\/jimmunol.0900265","article-title":"Immunization with the DNA-encoding N-terminal domain of proteophosphoglycan of Leishmania donovani generates Th1-type immunoprotective response against experimental visceral leishmaniasis","volume":"183","author":"Samant","year":"2009","journal-title":"J Immunol"},{"issue":"15","key":"10.1016\/j.jmii.2022.06.003_bib25","doi-asserted-by":"crossref","first-page":"2900","DOI":"10.1016\/j.vaccine.2005.12.053","article-title":"Leishmania donovani: identification of stimulatory soluble antigenic proteins using cured human and hamster lymphocytes for their prophylactic potential against visceral leishmaniasis","volume":"24","author":"Garg","year":"2006","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.jmii.2022.06.003_bib26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","article-title":"Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method","volume":"25","author":"Livak","year":"2001","journal-title":"Methods"},{"key":"10.1016\/j.jmii.2022.06.003_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2017.00217","article-title":"A vaccine therapy for canine visceral leishmaniasis promoted significant improvement of clinical and immune status with reduction in parasite burden","volume":"8","author":"Roatt","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.jmii.2022.06.003_bib28","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.3389\/fimmu.2017.01779","article-title":"Alternative to chemotherapy-the unmet demand against leishmaniasis","volume":"8","author":"Didwania","year":"2017","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.jmii.2022.06.003_bib29","doi-asserted-by":"crossref","first-page":"5819","DOI":"10.1128\/AAC.00273-15","article-title":"Sequential chemoimmunotherapy of experimental visceral leishmaniasis using a single low dose of liposomal amphotericin B and a novel DNA vaccine candidate","volume":"59","author":"Seifert","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"issue":"345","key":"10.1016\/j.jmii.2022.06.003_bib30","article-title":"Protective cellular immune response induction for cutaneous leishmaniasis by a new Immunochemotherapy schedule","volume":"11","author":"da Silva","year":"2020","journal-title":"Front Immunol"},{"issue":"2","key":"10.1016\/j.jmii.2022.06.003_bib31","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.4049\/jimmunol.181.2.1386","article-title":"Complete cure of experimental visceral leishmaniasis with amphotericin B in stearylamine-bearing cationic liposomes involves down-regulation of IL-10 and favorable T cell responses","volume":"181","author":"Banerjee","year":"2008","journal-title":"J Immunol"},{"issue":"2","key":"10.1016\/j.jmii.2022.06.003_bib32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.clim.2005.06.015","article-title":"T cell subset and cytokine profiles in human visceral leishmaniasis during active and asymptomatic or sub-clinical infection with Leishmania donovani","volume":"117","author":"Hailu","year":"2005","journal-title":"Clin Immunol"},{"key":"10.1016\/j.jmii.2022.06.003_bib33","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molimm.2018.08.004","article-title":"Induction of protective cellular immune responses against experimental visceral leishmaniasis mediated by dendritic cells pulsed with the N-terminal domain of Leishmania infantum elongation factor-2 and CpG oligodeoxynucleotides","volume":"103","author":"Agallou","year":"2018","journal-title":"Mol Immunol"},{"key":"10.1016\/j.jmii.2022.06.003_bib34","doi-asserted-by":"crossref","DOI":"10.1186\/s13071-016-1412-x","article-title":"Regulation of immunity during visceral Leishmania infection","volume":"9","author":"Rodrigues","year":"2016","journal-title":"Parasit Vectors"},{"key":"10.1016\/j.jmii.2022.06.003_bib35","doi-asserted-by":"crossref","first-page":"288","DOI":"10.3389\/fimmu.2019.00288","article-title":"Immunogenicity and protective efficacy of T-cell epitopes derived from potential Th1 stimulatory proteins of Leishmania (Leishmania) donovani","volume":"10","author":"Joshi","year":"2019","journal-title":"Front Immunol"},{"key":"10.1016\/j.jmii.2022.06.003_bib36","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/8845826","article-title":"A chimera of Th1 stimulatory proteins of Leishmania donovani offers moderate immunotherapeutic efficacy with a Th1-inclined immune response against visceral leishmaniasis","volume":"2021","author":"Ratnapriya","year":"2021","journal-title":"Biomed Res Int"},{"key":"10.1016\/j.jmii.2022.06.003_bib37","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fimmu.2012.00301","article-title":"Protective and pathologic immune responses in human tegumentary leishmaniasis","volume":"3","author":"Carvalho","year":"2012","journal-title":"Front Immunol"},{"key":"10.1016\/j.jmii.2022.06.003_bib38","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.0105-2896.2004.00188.x","article-title":"The immunopathology of experimental visceral leishmaniasis","volume":"201","author":"Kaye","year":"2004","journal-title":"Immunol Rev"},{"issue":"7","key":"10.1016\/j.jmii.2022.06.003_bib39","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1084\/jem.185.7.1231","article-title":"Intracellular antimicrobial activity in the absence of interferon-gamma: effect of interleukin-12 in experimental visceral leishmaniasis in interferon-gamma gene-disrupted mice","volume":"185","author":"Taylor","year":"1997","journal-title":"J Exp Med"},{"issue":"7","key":"10.1016\/j.jmii.2022.06.003_bib40","doi-asserted-by":"crossref","first-page":"901","DOI":"10.2217\/fmb.14.43","article-title":"Immunity to visceral leishmaniasis: implications for immunotherapy","volume":"9","author":"Khadem","year":"2014","journal-title":"Fut Microbiol"}],"container-title":["Journal of Microbiology, Immunology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118222000949?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1684118222000949?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T13:30:04Z","timestamp":1761658204000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1684118222000949"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S1684118222000949"],"URL":"https:\/\/doi.org\/10.1016\/j.jmii.2022.06.003","relation":{},"ISSN":["1684-1182"],"issn-type":[{"value":"1684-1182","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Combined immunotherapeutic effect of Leishmania-derived recombinant aldolase and Ambisome against experimental visceral leishmaniasis","name":"articletitle","label":"Article Title"},{"value":"Journal of Microbiology, Immunology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jmii.2022.06.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC.","name":"copyright","label":"Copyright"}]}}